Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with 12% revenue growth and improved gross margins. Net loss reduction and a significant increase in adjusted EBITDA also support a positive outlook. Despite risks associated with non-GAAP metrics, these financial improvements and strategic partnerships, such as with CareCredit, are likely to drive a positive stock price movement over the next two weeks.
Revenue Revenue for Q1 2026 was $45.3 million, representing a 12% increase year-over-year. This growth was driven by strong customer acquisition and retention efforts.
Gross Margin Gross margin improved to 72% in Q1 2026, up from 70% in Q1 2025. The improvement was attributed to operational efficiencies and cost management initiatives.
Net Loss Net loss for Q1 2026 was $3.2 million, compared to $4.5 million in Q1 2025. The reduction in net loss was due to increased revenue and improved cost controls.
Operating Expenses Operating expenses were $30 million in Q1 2026, a 5% increase year-over-year. The increase was primarily due to investments in sales and marketing.
Adjusted EBITDA Adjusted EBITDA was $5 million in Q1 2026, compared to $3 million in Q1 2025, reflecting a 67% improvement. This was driven by revenue growth and better expense management.
The selected topic was not discussed during the call.
Forward-looking statements: The company acknowledges that forward-looking statements are subject to various risks and uncertainties, which could impact anticipated business performance.
Non-GAAP metrics: The reliance on non-GAAP metrics, excluding certain costs, may obscure the full financial picture and pose challenges in assessing the company's true financial health.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The earnings call highlights strong financial performance with 12% revenue growth and improved gross margins. Net loss reduction and a significant increase in adjusted EBITDA also support a positive outlook. Despite risks associated with non-GAAP metrics, these financial improvements and strategic partnerships, such as with CareCredit, are likely to drive a positive stock price movement over the next two weeks.
The earnings call reveals strong revenue growth, improved gross margins, and increased free cash flow, suggesting financial strength. The company is raising its revenue and operating income guidance, indicating confidence in future performance. Expansion in AI and specialty medical verticals, alongside a new CareCredit partnership, further supports growth prospects. Despite some uncertainties in growth rates and product impacts, the overall sentiment is positive due to strategic initiatives and financial improvements.
The earnings call highlights strong financial performance, strategic growth through AI and partnerships, and optimistic guidance. While there are concerns about unclear management responses on payment adoption and future investments, the overall sentiment remains positive due to expected revenue growth, profitability improvements, and strategic initiatives. The market strategy and shareholder return plan are well-received, with plans for increased leverage and focus on high-potential verticals. Despite some uncertainties, the positive outlook on growth and profitability, along with strategic developments, suggests a positive stock price movement.
The earnings call highlights strong growth in specialty medical, successful integration of TrueLark, and positive customer feedback. The company's strategic investments in R&D and sales/marketing, along with raised revenue guidance, indicate a positive outlook. While there are some uncertainties regarding AI adoption and macroeconomic impacts, overall, the sentiment is positive due to strong demand, growth opportunities, and strategic plans. The Q&A section reinforces confidence in the company's direction, with analysts showing interest in growth strategies and integration progress.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.